Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Development and Piloting of 'Power Up': a Tool for Young People with Internalising/emotional Disorders to Make Shared Decisions in Child and Adolescent Mental Health Services (CAMHS)
Brief Summary: Patients should be able to have a say in their care and treatment, but how this should work for children and young people with mental health difficulties is unknown. For example, how and when do young people want to be involved in decision making, and what is important to them, their parents/guardians and healthcare professionals? This project will address these questions and will develop a tool known as 'Power Up' to help young people with mental health difficulties make decisions about their own care and treatment.

This project will run for 24 months and will:

1. Understand the beliefs, experiences, and values of young people, their parents/guardians and clinicians around shared decision making (SDM) in mental health.
2. Use these responses to develop 'Power Up'; a tool to help young people make decisions about their care or treatment in mental health services.
3. Pilot 'Power 'Up' in child and adolescent mental health services to estimate the number of patients who would want to use Power Up and to see whether patients can be recruited and followed up with measures. The pilot study would investigate randomisation, see how clinicians cooperate, and identify barriers to collaboration and ways of overcoming these.

Forty five young people, parents and clinicians will be recruited for interviews and focus groups to inform tool development. Sixty young people aged 1116 will be recruited for the pilot/feasibility study. Measurements will be collected at baseline, session by session, and at the end of treatment.


Options:
A: Inclusion Criteria:

1. A young person between 11 and 16 years of age with an emotional/internalising disorder who is accessing CAMHS.
2. A parent/guardian of a young person between 11 and 16 years of age with an emotional/internalising disorder who is accessing CAMHS.
3. A clinician in a participating CAMHS site.
4. Only those providing consent will be included. Where potential participants are under 16 parents/legal guardians will also have to provide consent.

Exclusion Criteria:

1. Any individual who is not accessing a participating CAMHS site.
2. Given there are no additional resources for an interpreter, children or parents who are not comfortable with English may not be included
3. Young people under the age of 11, or over the age of 16 would not be included.
4. Parents/guardians of young people with SEN (special educational needs) will not be included
5. Those who do not consent.
B: Inclusion criteria:

1. Are females aged \>18 years old, and
2. Are either planning a pregnancy OR are \<30 weeks gestation at enrollment, and
3. Have been offered to start or continue SSRI or SNRI anti-depressant medication as a treatment option for depression by their clinical provider at one of the study sites, and
4. Have moderate-to-high decisional conflict (score of \>25 on the Decisional Conflict Scale)

Exclusion criteria:

1. Have had alcohol or substance abuse or dependence in the previous 12 months, or
2. Have active suicidal ideation or psychosis, or
3. Are incapable of consenting to participation, or
4. Have any major obstetrical complications or fetal cardiac anomaly in the current or in a past pregnancy (as this changes the risk/benefit ratio discussion in regards to antidepressant use), or
5. Are unable to read or unable to speak or understand English and do not have someone that can read the PDA to them, or
6. Have a visual impairment that would prevent them from being able to view the website.
C: Inclusion Criteria:

* Over 18 years old
* Diagnosed with of severe OSA (AHI ≥ 30 events/hour)
* Discontinuation of CPAP 4 to 12 months after initiation Followed by the home health care provider Agiradom
* Access to a computer and/or tablet and an internet connection
* Oral and written French
* Able to provide written informed consent
* Affiliated to social security or beneficiary of such a scheme

Exclusion Criteria:

* CPAP cessation due to a resolution of the OSAS (e.g. weight loss after bariatric surgery) or another pathology that prevents the continuation of treatment (e.g. ENT surgery, etc.).
* Severe and/or unstable comorbidity that required hospitalisation for decompensation in the previous year (heart, kidney, respiratory, liver, psychiatric or other insufficiency).
* Patient being treated with a mandibular advancement orthosis
* Lack of availability (e.g. night worker or patient who travels frequently, etc.).
* Current participation in, participation in the month prior to inclusion in another clinical intervention research study that may impact the study: this impact is left to the investigator's discretion.
* Referred to in Articles L1121-5 to L1121-8 of the CSP (corresponds to all protected persons: pregnant woman, breastfeeding mother, person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure)
D: Inclusion Criteria:

* Age: 65 years and older;
* Medical outpatient presenting to Lincoln Hospital, Bronx NY, the New York City Health and Hospitals Corporation (HHC);
* Screen positive (PHQ-9 score\>9 for depression, in addition to primary care physician recommendation for depression treatment.

Exclusion Criteria:

* Presence of significant alcohol or substance abuse, psychotic disorder, or bipolar disorder;
* High suicide risk, i.e. intent or plan to attempt suicide in near future;
* Current treatment with antidepressant medication or psychotherapy prior to index physician visit (with the exception of low doses of antidepressant medication for pain disorders);
* Cognitive impairment: MMSE score \<20 or clinical diagnosis of dementia;
* Acute or severe medical illness, i.e., delirium, metastatic cancer, decompensated cardiac, liver, or kidney failure, major surgery, stroke or myocardial infarction during the three months prior to entry; or drugs often causing depression, e.g., steroids, reserpine, alpha-methyl-dopa, tamoxifen, vincristine;
* Aphasia interfering with communication.

Answer: A